Adherence With Oral Medsan Issue In Breast Cancer Drugs Dont Work In
Patients Who Dont Take Them

Adherence With Oral Medsan Issue In Breast Cancer Drugs Dont Work In Patients Who Dont Take Them



Adherence With Oral MedsAn Issue In Breast Cancer


​Drug​s dont work in patients who dont take them. In the​ battle against breast cancer, patients are increasingly prescribed oral medications, such as​ hormonal therapy, to limit the​ risk of​ disease recurrence. ​
Research has indicated that patients should stay on these ​Drug​s for​ five years to gain maximum benefits. ​

But recently, the​ healthcare community has started to ask a​ question once limited to managing common colds, not cancer Do breast cancer patients take their medications as​ prescribed?
According to the​ American Cancer Society, more than 200,000 new cases of​ breast cancer are diagnosed every year in the​ U.S. ​
of​ those, approximately 100,000 have cancer types that are likely to respond to hormonal therapy. ​
Taking the​ therapy as​ prescribed for​ the​ full five years can reduce their risk of​ recurrence. ​

Easier Said than Done
Based on findings from a​ recent symposium on medication adherence among breast cancer patients, candidates for​ hormonal therapysome 500,000 women in the​ U.S.may not be reaping the​ full benefits of​ their ​Drug​ regimens. ​
According to some research studies, noncompliance rates have reached as​ high as​ 40 percent.
The Symposium, called the​ Compliance Strategic Initiative CSI, addressed issues that lead to medication noncompliance among breast cancer patients, and​ ​ it​ identified possible solutions to these issues. ​
Representatives from leading patient advocacy organizations and​ ​ professional healthcare associations, as​ well as​ oncology experts and​ ​ survivors from across the​ nation, gathered to share their perspectives. ​
The CSI was led by a​ Steering Committee which included representatives from the​ American Cancer Society, CancerCare, the​ National Surgical Adjuvant Breast and​ ​ Bowel Project NSABP, and​ ​ YME National Breast Cancer Organization.
Through research, we know that five years of​ adjuvant hormonal therapy in women with estrogen receptorpositive breast cancer prolongs survival and​ ​ reduces recurrence, said D. ​
Lawrence Wickerham, MD, associate chairman of​ the​ National Surgical Adjuvant Breast and​ ​ Bowel Project. ​
And yet, studies also show that not all patients stay on hormonal therapy as​ prescribed. ​
it​ is​ important that healthcare providers understand why women make that decision, so we can address the​ issue with the​ information, resources and​ ​ support needed to help them through this part of​ their treatment.
Based on results of​ the​ meeting, participants gained a​ better understanding of​ the​ factors that contributed to noncompliance. ​
Among those factors patients often do not feel empowered to talk with their doctors about tough issues, such as​ side effects; doctors and​ ​ other healthcare professionals arent equipped with resources to assist patients in coping with or​ eliminating side effects; and​ ​ after their acute phase of​ treatment, women may often feel they are left to manage therapy on their own. ​
Physicians are under increasing pressures of​ time and​ ​ performance and​ ​ may not always have the​ skill set to listen well to their patients, or, simply not realize their patients may not be taking their medication. ​
These factors combine to create communication gaps through which compliance issues can fall. ​

In conclusion, breast oncology advocates and​ ​ experts who attended the​ symposium agreed that patient support mechanisms can and​ ​ must be improved. ​
Healthcare providers and​ ​ patients each play pivotal roles. ​
Through education and​ ​ communication, they can begin to take the​ steps that will help some breast cancer patients reduce their risk of​ recurrence. ​

Two in five breast cancer patients dont take their medication properly.




Related Articles:




Powered by Blogger.